EXPERIENCE
Dr. Andrew Hack joined Bain Capital in 2019. He is a Partner on the Life Sciences team.
Prior to joining Bain Capital, Andrew was Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) where he had responsibility for finance, investor relations, business development, information technology, and operations. Previously, he served as a portfolio manager at Millennium Management, where he ran a market-neutral healthcare hedge fund focused on biotechnology, pharmaceutical, medical device and diagnostics, and life science tools companies. Earlier in his investment career, Andrew was a securities analyst at a number of healthcare-focused hedge funds and investment banks in New York. Prior to this, he was Director of Life Sciences at Reify Corporation, a life science tools and drug discovery company.
EDUCATION
Andrew received an MD and PhD in molecular genetics and cell biology from the University of Chicago, where he was named an inaugural Frank Family Scholar and received awards from the American Heart Association and the American Society for Cell Biology. He graduated with Special Honors from the University of Chicago with an AB in biology.
